Use of reclaimed wastewater for agricultural irrigation is seen as an attractive option to meet agricultural water demands of a growing number of countries suffering from water scarcity. However, reclaimed wastewater contains pollutants which are introduced to the agro-environment during the irrigation process. While water reuse guidelines do consider selected classes of pollutants, they do not account for the presence of pollutants of emerging concern such as pharmaceuticals and the potential risks these may pose. Here we use source-pathway-receptor analysis (S-P-R) to develop a holistic framework for evaluating the impacts of pharmaceuticals, present in wastewater used for agricultural irrigation, on human and ecosystem health and evaluate the data availability for the framework components. The developed framework comprised of 34 processes and compartments but a good level of knowledge was available for only five of these suggesting that currently it is not possible to fully establish the impacts of pharmaceuticals in wastewater irrigation systems. To address this, work is urgently needed to understand the fate and transport of pharmaceuticals in arable soil systems and the effects of chronic low-level exposure to these substances on microbes, invertebrates, plants, wildlife and humans. In addition, research pertaining to the fate, uptake and effects of pharmaceutical mixtures and metabolites is lacking as well as data on bio-accessibility of pharmaceuticals after ingestion. Scientific advancements in the five areas prioritised in terms of future research are needed before we are able to fully quantify the agricultural and human health risks associated with reclaimed wastewater use.
Introduction and background
Water management is an issue of global concern; a recent World Bank report concluded that water scarcity, exacerbated by climate change, could cost some regions up to 6% of their GDP, spur migration and spark conict.
1 To meet the growing demand for water, treated wastewater (reclaimed wastewater) is sometimes reclaimed and used to irrigate agricultural land, golf courses and various other landscapes. Use of reclaimed wastewater is an especially attractive option in countries suffering from water shortages that have a typically warmer and dryer climate such as in the Middle East and Southern Europe.
2-5 In Israel, for example, more than 85% of the produced reclaimed wastewater is currently used for irrigation. This accounts for over 50% of the total irrigation volume. 6, 7 Comparatively, use of reclaimed wastewater for agricultural irrigation in California only amounts for about 4% of the irrigation volume, but this has been increasing steadily. Due to anticipated water shortages, the state has developed a policy calling for a threefold increase in the total reuse of reclaimed wastewater by 2030. 8 Despite recent advances in technologies to treat wastewater, some pollutants of emerging concern such as pharmaceuticals and personal care products are not removed by wastewater treatment. 9, 10 These chemicals are frequently detected in both raw inuent and treated effluents of wastewater treatment plants at concentrations ranging from ng L À1 to mgL À1 .
11,12
Concentrations of pharmaceuticals in wastewater vary across the globe. For example, the concentrations of a vast majority of antibiotics in effluents are generally higher in most Asian countries than those reported in European and North America 10, [13] [14] [15] with high concentrations explained by: high consumption and the fact that these compounds are readily available in these regions; and poor wastewater treatment technologies in some regions. In addition, different treatment technologies remove different chemicals to different extents thereby resulting in a range of concentrations in effluents. Concentrations of acetaminophen, for example, have been observed to range between below method detection limits to 62 000 ng L À1 across wastewater treatment plants sampled in North America and Asia. 12 An increasing number of studies have documented the presence of a wide range pharmaceuticals destined for land application. [16] [17] [18] With the anticipated future increases in reclaimed wastewater reuse expected on a global scale (e.g. FAO report "Coping with water scarcity: an action framework for agriculture and food security"), 19 the introduction of pharmaceuticals to agro-environments is also expected to increase. At the EU level it has been acknowledged that we need to develop minimum requirements to manage the human and environmental risks from reclaimed wastewater to irrigate crops (COM(2018)337).
20
Classication of reclaimed wastewater destined for agricultural irrigation has therefore been proposed and this is based on monitoring for the presence of pathogens and physico-chemical constituents that may pose a risk to human and environmental health, and to environmental matrices (e.g. E. coli, biological oxygen demand, turbidity, and suspended solids). 21 The proposed quality requirements for the EU are similar to the WHO Guidelines for the Safe Use of Wastewater, Excreta and Greywater 22 and the Australian Guidelines for Water Recycling (Phase 1) 23 when wastewater is used to irrigate of urban, recreational and open space, and agriculture and horticulture.
While, in some regions, the human health risks of pharmaceuticals are accounted for when wastewater is used for drinking water purposes (e.g. Australian Guidelines for Water Reuse: Augmentation of Drinking Water Supplies), 24 there are currently no quality standards with regards to concentrations of pharmaceuticals in reclaimed wastewater used for irrigation. Given the current demand, and potential for future widespread use of reclaimed wastewater, it is essential we are able to adequately assess this risk. In order to contribute to the safe reuse of reclaimed wastewater in agriculture, policies and guidelines may need to be updated, and mitigation measures put in place to minimise environmental and human health impacts. There is therefore a need to develop new frameworks for determining the impacts of pharmaceuticals present in wastewater irrigation systems on agro-ecosystem and human health. In this paper, we therefore present a Source-PathwayReceptor (S-P-R) analysis to establish a framework to describe how pharmaceuticals originating from reclaimed wastewater could impact on human health and the health of agricultural systems. We then assess the availability of knowledge, data, models and methods required to populate different components of the S-P-R diagram.
Source-pathway-receptor analysis
The S-P-R diagram, consisting of 34 compartments (A-K), represents the different pathways in which agro-ecosystems are exposed to pharmaceuticals receiving wastewater irrigation (Fig. 1) . The primary source of pharmaceuticals is reclaimed wastewater used as a source of irrigation (A; Fig. 1 ) according to agricultural water management systems (B; Fig. 1 ). This results in the contamination of a number of environmental compartments identied as the soil, surface water and groundwater (C, D and F; Fig. 1 ). A range of receptors can then be exposed to pharmaceuticals in these compartments through a variety of direct and indirect pathways. The main receptors identied include terrestrial wildlife, people, livestock, terrestrial plants, soil fauna and aquatic species (F-K; Fig. 1) , with a number of receptors themselves identied as potential routes (secondary sources) of exposure for pharmaceutical contamination via food web transfer to higher vertebrates in the food chain (e.g. sh as a source of food for birds). Whilst this analysis considers the use of reclaimed wastewater as the route for pharmaceuticals to enter agroecosystems, the use of organic soil amendments (sludges and/or livestock manures) are also signicant pathways by which pharmaceuticals can enter, and become omnipresent, in soils. 25, 26 A number of associated risks and knowledge gaps highlighted in this analysis are therefore also relevant to these additional pathways (Table 1) .
Knowledge and data availability
Sources (A-B). Reclaimed wastewater has been used as a source of agricultural irrigation in Asia, the Mediterranean and other arid and semi-arid regions for centuries (A; Fig. 1 and 2). Where there are policies in place to ensure food security and sustainable water management, the use of reclaimed wastewater comes under the broad umbrella of Agricultural Water Management Systems (B; Fig. 1 ). For example, Israel has one of the largest water recycling initiatives, where the use of reclaimed wastewater, comes under the Long Term National Water Sector Master Plan (LTN-MP).
7 Direct use of reclaimed wastewater varies on a country-by-country basis. For example, it was estimated that reclaimed wastewater in China accounted for 1.26 Â 10 9 m 3 of agricultural irrigation water in 2013, which was approximately 10 times greater than reclaimed wastewater use in the United Arab Emirates at 0.14 Â 10 9 m 3 .
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In an attempt to augment growing water demands, untreated wastewater is also used as a source of irrigation where wastewater infrastructure is lacking or where wastewater has undergone little to no treatment. For example in Mexico approximately 2 60 000 ha are irrigated with wastewater, most of which is untreated.
2 There is an urgent need to identify where raw or partially treated wastewater is being used in agriculture to enable the risks to be properly assessed given that estimates indicate that at least 20 million hectares in 50 countries are irrigated with raw or partially wastewater.
28,29
Through global monitoring campaigns we have a good understanding of the typical concentrations of pharmaceuticals in wastewater treatment plant (WWTP) effluent for some regions. [30] [31] [32] According to a recent report by aus van der Beek, 33 pharmaceuticals identied in treated wastewater comprise 28% of all global monitoring data with concentrations of a single pharmaceutical being reported up to 43 900 mgL
À1
. However, of the approximately 1500 pharmaceuticals estimated to be currently in use, 34 monitoring studies have only identied $550 active pharmaceutical ingredients in wastewater effluent (according to data reported on UBA Database: Pharmaceuticals in the Environment) (Table 2) . 33, 35 In addition, monitoring studies have primarily centred on the quantication of pharmaceutical parent compounds with little effort made to identify the presence of metabolites and other transformation products. 36, 37 To add further complexity, for some geographic regions there is also limited or non-existent monitoring data on concentrations of pharmaceuticals in wastewater. 33 If we do not have a clear picture of the quantities and types of pharmaceuticals and their transformation products in reclaimed wastewater this poses a major challenge when trying to assess the global risks associated with wastewater reuse in agriculture.
Predictive modelling approaches, such as the multimedia box model SimpleTreat, offer a means of generating data on concentrations of pharmaceuticals in wastewater effluent by estimating chemical fate in activated sludge WWTPs. 38 A recent evaluation found that, in general, SimpleTreat 4.0 was able to predict concentrations of pharmaceuticals in effluents to within a factor of 10 of measured concentrations. 39 However, predictive approaches such as this typically require a large amounts of input data, for example information on pharmaceutical usage, sorption to sludge, and degree of chemical biodegradability. The availability of this data, which currently exists for a limited number of compounds, constrains model use in the rst instance. On-going research to develop Quantitative Structure Property Relationships (QSPRs) to describe pharmaceutical sludge sorption and biodegradability 40, 41 and high-throughput approaches to identify transformation products 42 will enable us to better model wastewater effluent concentrations in the future. In addition, models such as SimpleTreat are parametrised under the assumption that the WWTP is functioning correctly, and in some regions (e.g. Palestine), this is probably not the case, which will alter concentrations of pharmaceuticals in wastewater and thus the exposure to the agro-environment. We need to therefore understand the performance of different treatment technologies in different regions and further develop models to account for these differences.
In order to regulate peak demands as well as uctuations in effluent ow, reclaimed wastewater is oen stored in a reservoir and the inuence of storage on chemical fate for a range of pharmaceuticals is largely unknown. 43, 44 However, published models that account for dissipation in water could be utilised to explore this further in combination with improved QSPRs for persistence in the water column and a greater understanding of reclaimed wastewater storage e.g. depth of reservoir, residence time in reservoir. In addition, research is needed to explore the chemical fate processes of pharmaceuticals during pipe ow to agricultural elds and during the drip irrigation process itself 34, 146 -Occupational exposure 157 
13
Soil to terrestrial wildlife -Limited information for some pharmaceuticals 69, 158 -No data for most compounds Low which have the potential to inuence pharmaceutical retardation and/or degradation however very little is known about these processes.
Compartments (C-E).
Reclaimed wastewater irrigation can result in the contamination of a number of environmental compartments including soils, surface water and groundwater (Table 2, Fig. 1 ). Continuous application of reclaimed wastewater to land has resulted in pharmaceuticals building up to detectable concentrations in soils (up to ca. 15 mgk g À1 ) ( Fig. 1; pathway  1) . [46] [47] [48] Despite analytical challenges associated with quantifying pharmaceuticals in complex environmental samples 49 (e.g. matrix interference, validated extraction methodologies) we have a good understanding of the fate of many pharmaceuticals in soils. A combination of experimental studies and modelling approaches have explored processes such as the sorption, leaching and degradation of pharmaceuticals. [50] [51] [52] However, these efforts have typically focussed on the direct application of pharmaceuticals to soil and neglected to account for the presence of the reclaimed wastewater. The degradation of a limited number of pharmaceuticals in reclaimed wastewater-irrigated soils have so far been investigated. 17, 48, 53 Treated effluents have been shown to increase the mobility of weakly acidic pharmaceuticals 16 with microbial activity, dissolved matter, nutrients and particulate matter in reclaimed wastewater observed to affect the half-life of pharmaceuticals. 54 However, further analysis is needed to explore the discrepancy between laboratory studies and results from eld experiments when evaluating the fate of the pharmaceuticals in soils. Pharmaceuticals, such as sulfamethoxazole, are increasingly observed to persist in the eld 47 for much longer than expected based on half-lives generated from laboratory experiments would predict.
51,55
Pollutants themselves can also alter soil microbial communities (as discussed under 'Receptor' section below) which have the potential to affect chemical degradability. 52 This highlights the need to consider the composition of reclaimed wastewater and the alteration of the "reactivity" of soil microbial communities when evaluating the fate of pharmaceuticals aer land application as these factors can have indirect effects on the fate of pollutants. In addition, long term reclaimed wastewater irrigation can lead to an alteration of soil properties (e.g. pH, heavy metals and nutrient content) which can in turn affect the fate of soil pollutants and this is something we know very little about.
Research has already highlighted the signicant role soil properties play in the sorption and degradation of 41 to account for the signicant role soil properties play in the fate of pharmaceuticals. In addition, fate modelling of pharmaceuticals should consider soil, hydrological and climatic factors that will alter in the future in response to a changing climate.
In addition to detecting pharmaceuticals in soils, monitoring campaigns have quantied the presence of pharmaceuticals in surface waters across the globe, however it is assumed this largely originates from the direct release of WWTP effluent.
59,60 A small number of studies have demonstrated the mobilisation of pharmaceuticals following biosolids application to land 25, 61 however much less is known about the contribution of surface run-off to the contamination of water bodies aer treated wastewater irrigation (pathway 3).
18 Pharmaceuticals can also migrate from soils and contaminate groundwater supplies via leaching aer reclaimed wastewater irrigation, with reported concentrations in groundwater typically being in the range of low ng L À1 ( Fig. 1; pathway 2) . 53, 62, 63 However our understanding of the potential for the migration of pharmaceuticals to groundwater is primarily limited to a small number of soil 63 This would suggest that soil has a limited capacity to act as a biogeochemical lter before the wastewater recharges underlying aquifers. More research is needed to understand the spatial-temporal factors inuencing groundwater contamination including an evaluation of the potential pathway for pharmaceuticals to migrate to surface water from contaminated groundwater. Models have been developed to capture the transport of plant protection chemicals through the soil prole leaching into groundwater (e.g. FOCUS PEARL), but these models were not specically parameterised for pharmaceuticals. Given the chemical similarity between plant protection products and pharmaceuticals (e.g. molecular weight, pK a within ionisable range) it is expected that these models will provide a good estimation as to the fate and transport of pharmaceuticals in soil. These models may however need to be rened to account for the effect of the reclaimed wastewater matrix on pharmaceutical transport. Studies on veterinary pharmaceuticals in soils have shown that these models under predict exposure, possibly due to colloid-facilitated transport of the pharmaceuticals.
Examples of monitored drugs
Analgesic 33 3 3 -- - 3 - 3 Acetaminophen Antibiotic 33 3 3 -- - 3 - 3 Ciprooxacin, clarithromycin Antidepressant 33 3 3 -- - 3 - 3 Fluoxetine Antidiabetic 33 3 -- - 3 - 3 Metformin Antiepileptic 33 3 3 - 3 - 3 - 3 Carbamazepine, lamotrigine Antihypertensive 33 3 3 -- - 3 - 3 Atenolol, metoprolol Anti-inammatory 33 3 3 3 -- 3 - 3 Naproxen, diclofenac Antineoplastic 3 - 33 -- - - - 3 Carboplatin, 5-uorouracil Antipsychotic 3 - 33 -- - 3 - 3 Diazepam, oxazepam Antiviral 3 - 33 -- - - - -Nevirapine,
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As well as reclaimed wastewater, surface and ground waters can also be used as a source of irrigation water thereby transferring these contaminants back into the soil environment. Abstraction of contaminated ground and surface water for irrigation is generally well characterised where such practices exist ( Fig. 1 ; pathway 4 and 5), however our understanding of the transfer of pharmaceuticals from surface water to ground water via inltration is limited to a select number of chemicals ( Fig. 1; pathway 6) . 66 Heberer et al., demonstrated that whilst bank ltration can decrease the concentration of certain pharmaceuticals (dilution and/or removal) pharmaceutically active substances are still present in sampled ground waters at bank ltration sites. 67 Similarly, the use of reclaimed wastewater to support aquaculture is known to be practiced 68 although we have limited understanding of the specic locations and volumes of water used which presents a challenge with regards to quantifying the presence of pharmaceuticals in these systems ( Fig. 1; pathway 7) .
Receptors (F-K). Contamination of soil, surface and ground water presents a risk to receptors which feed on, or inhabit, these compartments. The main receptors considered in this analysis include humans, terrestrial wildlife, livestock, terrestrial plants, aquatic species and the soil microbial community (Fig. 1) . The biological potency of pharmaceuticals means that the occurrence of these chemicals in agro-ecosystems has the potential to induce toxic effects in these non-target organisms.
69
To meet the growing demand for water and to ensure sustainable use of reclaimed wastewater irrigation it is imperative to understand the pathways by which these receptors are exposed (Fig. 1, Table 1 ), the propensity for accumulation as well as the levels at which effects are observed. Research efforts to answer these questions are summarised below.
Terrestrial plants. A range of different crops have been shown to accumulate pharmaceuticals from soil ( Fig. 1; pathway 10) , including root vegetables (e.g. carrots, radish), fruits (e.g. tomatoes, cucumber), leaves (e.g. lettuce, ryegrass) and grains (e.g. wheat). [70] [71] [72] However realistic exposure studies, for example eld trials using environmentally relevant irrigation regimes are limited in number. [72] [73] [74] [75] Uptake into a range of plant components has been studied, however we know very little about uptake into crops native to arid and semi-arid countries where reclaimed wastewater irrigation is widely practiced such as the Middle East where olive and g trees are frequently irrigated with reclaimed wastewater. We also have a limited understanding of the uptake of pharmaceuticals into plants via foliar application of wastewater ( Fig. 1; pathway 11 ) with previous research primarily focusing on quantifying uptake from soil. However, overhead irrigation should not be neglected as this has recently been shown to substantially increase pharmaceutical residues in lettuce leaves compared to surface irrigation of soils for a select number of pharmaceuticals.
76
Similarly to the quantication of pharmaceuticals in soils there are several challenges associated with the extraction and detection of pharmaceuticals in plant samples including the identication of metabolites. 77 Microbial driven processes can result in the formation of transformation products in soil, 78 as well as their presence resulting from the direct application of wastewater containing metabolites formed in the patient or transformation products formed in the treatment process.
48
Publications are also beginning to document in-plant metabolism/transformation of pharmaceuticals, particularly for the antiepileptic compound, carbamazepine.
6,79-82 Data generated to date show that metabolites can be present in plants at levels similar to or greater than the parent compound. 83 It is important to understand the transformation of a wider range of pharmaceuticals in soil-plant systems because the structure and polarity of metabolites can be drastically different from their parent compounds, and therefore it is expected that their fate, uptake and toxicity will be different.
77
Models exist to predict transport and whole plant allocation of organic chemicals, including uptake from soil and following foliar application. [84] [85] [86] [87] However, oen these models, which are either simple correlations with compound properties or more complex compartmental models, do oen not account for the complexity of the factors and processes determining pharmaceutical uptake, including chemical speciation, in-plant metabolism and differences in plant physiology. Given the widespread use of reclaimed wastewater, containing a range of pharmaceuticals to irrigate a globally diverse set of crops, it is impossible to gather experimental data for all these scenarios. It is therefore essential that new models, that cover a range of plant traits and exposure scenarios, are developed to predict the uptake of pharmaceuticals into plants, so we can adequately assess the risks arising from this accumulation. The development of models for individual compound classes and for separate plant species may therefore represent a promising approach for future model development.
88
Due to the biological potency of pharmaceuticals and their metabolites, accumulation of these chemicals in plants presents a risk to the health of the plant directly as well as to the organisms that feed on the plant material, including humans and terrestrial wildlife. For example, exposure of plants to antibiotics has been shown to affect plant biomass. [89] [90] [91] In addition to visible whole-plant morphological symptoms, pharmaceuticals have also been shown to have the potential to affect in-plant homeostasis, such as changes in phytohormones, cellular metabolism, nutrient uptake and signaling without phenotypic change. [92] [93] [94] [95] These changes at the subcellular scale and molecular level may be considered as the underlying mechanisms for the long-term visual phytotoxic responses, e.g., plant biomass effects. It is unsurprising that pharmaceutical induced effects have been observed given that these chemicals are designed to interact with specic molecular targets in humans and these targets have orthologs that are conserved in other species e.g. 20-25% the drug targets in humans had predicted orthologs in plants. 96 Specically, common receptors have been identied in plants for a number of antibiotics affecting plant physiological responses (e.g. chloroplast replication). 97 We need to understand the mechanisms driving these effect responses, whether they are a direct interaction between the chemical and a receptor or an indirect effect of the chemical affecting soil microbial homeostasis which is in turn affecting plant health (pathway 14; see below for more detail on soil microbial communities).
Soil fauna. As well as the potential to affect plants, prolonged effluent irrigation has been observed to effect the soil microbial community ( Fig. 1; pathway 8) . 98, 99 Research has primarily focussed on the effects of antibiotics, with publications documenting an inhibition of microbial activity, 100 and signicant dose-related effects on the soil microbial community function. 101 More research is needed to understand the effects of a wider suite of pharmaceuticals as well as the effects of mixtures on soil microbial communities and the recovery of soil microbial function in response to pharmaceutical dissipation in soil. It is also known that soil microbes provide an ecosystem service to humans however we know very little about the development, preservation and transfer of antimicrobial resistance via this route ( Fig. 1; pathway 19 ).
102
People. Accumulation of pharmaceuticals in edible crops presents a risk to humans that feed on reclaimed wastewater produce ( Fig. 1; pathway 17) . Paltiel et al. 103 were the rst to detect pharmaceutical residues in the urine of individuals consuming crops irrigated with reclaimed wastewater. Whilst this study clearly shows that humans can metabolise pharmaceuticals in plant material, the human health risk from ingesting this contaminated produce is largely debated. A number of studies have concluded that the risk to humans is negligible, with concentrations in edible plant tissue typically below permissible thresholds (e.g. acceptable daily intake (ADI)). 70, 104, 105 However, for certain pharmaceuticals, accumulation in edible plant organs has the potential to reach calculated toxicity thresholds. 73, 106 Ingestion of even low doses of pharmaceuticals may be a signicant issue for sensitive populations (e.g. elderly, children, pregnant women), individuals with allergies to particular medication, as well as increase the potential for contraindications between prescribed treatments and chemicals consumed in crops. With regards to antibiotics in particular, Williams-Nguyen et al. 102 highlighted that globally there is a lack of data on human exposure to antimicrobial resistance in agroenvironments which may result in a wider health issue. Ultimately, we know very little about the human health risks of consuming wastewater irrigated produce over the long-term. However, pharmaceuticals are arguably one of the most data rich groups of chemicals in terms of mammalian toxicology. There is a wealth of data on pharmaceutical therapeutic effects and occupational exposure limits and we need to exploit this, together with chemical read-across, to derive chemical specic ADIs, to better understand the human health risks of ingesting crops contaminated with pharmaceuticals. In addition to the consumption of contaminated crops, people are at risk of ingesting meat, sh, wildlife and drinking water contaminated with contaminants of emerging concern ( Fig. 1; pathways 12 , 16 and 24), however human exposure from multiple contami n a t e ds o u r c e ss u c ha st h i si sr a r e l yc o n s i d e r e di nr i s k assessment paradigms. Future research to evaluate the risks of ingesting pharmaceutical contaminated produce can utilise previously published approaches to assess the risks of dietary exposure (e.g. for pesticides) and incorporate dietary information and food sourcing information to generate an accurate assessment of pharmaceutical exposure.
Terrestrial wildlife. Wildlife species considered in this scenario includes soil invertebrates, birds and small mammals. Studies have so far identied that earthworms can accumulate pharmaceutical residues from soils, however research into other soil invertebrates is lacking.
107,108 Accumulation of pharmaceuticals into species at the base of the food chain, such as earthworms, presents a potential risk to top predators, which feed on these organisms ( Fig. 1; pathway 13 ). Our traditional approach to assessing food web transfer of chemical contaminants consists of simplistic exposure scenarios 109 where exposure originates from a single contaminated prey source. However, top predators such as birds are exposed to pharmaceuticals from multiple sources including ingestion of contaminated crops ( Fig. 1; pathway 18) , sh ( Fig. 1; pathway  21 ) and surface water ( Fig. 1; pathway 22 ) and risk assessment needs to account for these more complex exposure scenarios. We also need to further our understanding of the bioaccessibility of pharmaceuticals in wildlife; perhaps building on recent work that developed an in vitro gastrointestinal tract model to compare the bioaccessibility of the antidepressant uoxetine from invertebrate prey for birds and mammals using.
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Research regarding potential effects in non-target terrestrial wildlife remains scarce, 111, 112 with minimal data on long term exposure and distribution in higher vertebrates as well as the effects of pharmaceutical mixtures and transformation products. 69 Given that the decline of the Asian vulture population has been attributable to exposure of a commonly prescribed non-steroidal anti-inammatory, diclofenac, 113 and the current lack of exposure and effects data in this area, research efforts are needed to evaluate pharmaceutical contaminants in terrestrial wildlife systems. Specically, we need to advance our understanding of biomagnication and the effects of pharmaceuticals in food webs.
Livestock. Livestock can be exposed to pharmaceuticals by ingesting reclaimed wastewater irrigated crops as part of their diet ( Fig. 1; pathway 15 ) as well as using contaminated surface water as a source of drinking water ( Fig. 1; pathway 23 ). Even though these pathways have been identied, we have a limited understanding of the bio-accessibility of pharmaceuticals (and their metabolites) in livestock and potential effects of long-term exposure to these chemicals. We have an opportunity to utilise existing modelling approaches developed for assessing livestock exposure to persistent organic pollutants. 114 Use of these models in combination with mammalian toxicology data could enable progress to be made in understanding impacts of livestock exposure to pharmaceuticals.
Aquatic species. As the focus of this work is on terrestrial systems a number of key concepts are summarised briey below and the authors refer the reader to previously published reviews that comprehensively explore the accumulation of pharmaceuticals in aquatic systems. [115] [116] [117] Aquatic species can accumulate chemicals present in surface water via aqueous uptake of waterborne chemicals (bioconcentration), and dietary uptake by ingestion of contaminated food particles (biomagnication) ( Fig. 1; pathway 9 ). Whilst experimental protocols exist to evaluate the bioconcentration of chemicals, data only exists for a select number of pharmaceuticals and in a limited number of species, primarily sh. 118 Predictive approaches have been proposed to estimate bioconcentration factors (BCFs), however, with a focus on the accumulation of non-ionised pharmaceuticals by sh more work is needed to predict accumulation of contaminants of emerging concern by aquatic invertebrates and to account of the effects of ionisation on chemical uptake.
119
Research has also demonstrated that for a number of pharmaceuticals, uptake by aquatic organisms can induce chronic and acute effects, however little is known about the effects of mixtures which would be considered more realistic in terms of a typical environmental exposure. 120 To account for recent monitoring outputs, which have demonstrated the spatial and temporal variation of pharmaceuticals in surface waters (see earlier discussion), an evaluation of the effect of pharmaceuticals on aquatic organisms at varying scales, is needed. This adds signicant complexity and uncertainty to environmental risk assessment of surface waters as well as other environmental compartments known to be reservoirs of pharmaceuticals (e.g. soil).
Priorities for parameterising the S-P-R framework
As clearly identied, there are numerous major knowledge gaps pertaining to the risks of pharmaceuticals in agricultural systems receiving reclaimed wastewater. Based on our current understanding we are therefore not at a stage where we can fully evaluate the risks of pharmaceuticals in wastewater reuse systems. Table 1 summarises briey our current understanding and key knowledge gaps related to the sources, pathways and receptors of pharmaceuticals in agro-ecosystems. A synthesis of available data in combination with expert knowledge has enabled the components of the S-P-R diagram to be classied according to 'Poor', 'Moderate' or 'High' with regards to the level of understanding we have in each of these areas.
Of the 34 individual components of the S-P-R diagram we only have high level of understanding of 5 of these (Table 1) . We have a greater understanding of the sources of pharmaceuticals in reclaimed wastewater and irrigation practices whereas we only have a low moderate understanding of the processes by which pharmaceuticals move between sources and are taken up by receptors. As the fate and behaviour of most pharmaceuticals entering our agriculture systems remains poorly characterized, our conception and understanding of the risks posed to receptors is equally constrained.
Future research efforts should therefore seek to address ve main areas over the next 15-20 years ( Fig. 3) :
Analytical method development -Develop methods for a broader suite of pharmaceuticals (and metabolites) using techniques such as high resolution mass spectrometry to enable detection in a variety of complex matrices (e.g. plant tissue) at environmentally relevant concentrations.
-Use non-target screening approaches to explore the formation of biologically active metabolites (and conjugates) to complement targeted analysis based on identied Fig. 3 Possible time lines and strategy for prioritised research areas, to better understand the fate, uptake and effects of wastewater derived pharmaceuticals in agro-ecosystems.
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Environmental exposure
-Develop experimental datasets on the fate and reactivity of pharmaceuticals (and active metabolites and transformation products) in the environment following long-term and intensive irrigation with reclaimed wastewater.
-Account for the varying performance of different WWTP technologies in different regions and to provide a greater understanding on the use of raw or partially treated wastewater (including water used in aquaculture) for irrigation where sewage connectivity is limited or non-existent.
-Understand how future environmental change (e.g. increased temperature, drought) and agricultural developments (e.g. increased global food demand) will alter the environmental exposure of pharmaceuticals.
Uptake scenarios -Generation of experimental data sets to evaluate the uptake of pharmaceuticals, including metabolites and transformation products identied in reclaimed wastewater of formed in soils and plants, with particular focus on previously underexplored receptors such as wildlife and the potential for multigenerational exposure (e.g. via accumulation in seeds).
-Investigate the uptake of pharmaceuticals by receptors aer low-level chronic exposure and as well in response to mixture exposures.
-Determine the formation of pharmaceutical transformation products in receptors and identify metabolism pathways to help assist with predictive model development (see below).
-Identify key factors which alter the uptake, accumulation and bioaccessibility of pharmaceuticals in receptors accounting for species traits and exposure medium properties.
Uptake model development
-Parameterise and validate a holistic uptake model that accounts for the fate of chemicals in soil, interconnectivity between receptor uptake, bioaccessibility and metabolite formation for a wide suite of pharmaceuticals.
-Account for geographical and species variations in diets, food sourcing and exposure concentrations of pharmaceuticals.
Effects analysis
-Evaluate a wider suite of biological and physiological endpoints to elucidate the impact of biologically active pharmaceutical residues (including metabolites and mixtures) on soil and plant health (including soil fauna) with a view to understand implications for agricultural productivity.
-Investigate the suitability of analogous approaches to those adopted for predicting the effects of pharmaceuticals in the aquatic environment (e.g. chemical read-across).
-Develop thresholds to evaluate the human health risks from consuming produce containing pharmaceutical residues, considering chemical mixtures (i.e. likelihood of contraindications) and populations deemed most at risk (e.g. elderly, children).
Conclusions
The gap between water supply and water needs is growing; thus an integrated water resources management approach is required that utilises new sources of water for agricultural use such as reclaimed wastewater. However, we should ensure that this is done in a safe and sustainable manner and therefore the associated risks associated with such practices must be evaluated.
Use of reclaimed wastewater irrigation results in the contamination of a number of environmental compartments, each of which can act as reservoirs of pharmaceuticals. These chemicals have the potential to accumulate in a variety of receptors including terrestrial wildlife, livestock, terrestrial plants, aquatic species, soil microbial community and humans, posing a range of potential health and environmental challenges. This risk may be greatest in low to middle income countries where wastewater treatment technologies are limited or oen non-existent leading to an increased use of semi treated or non-treated wastewater.
A number of broad knowledge gaps were identied, most notably that more research is needed to consider the effect of metabolites on the various pathways and receptors highlighted in Fig. 1 . In addition, research pertaining to the effect and fate of pharmaceutical mixtures are lacking as well as data on bio accessibility of pharmaceuticals aer ingestion by humans, wildlife and livestock. Ultimately, use of reclaimed wastewater will require a trade-off between the economic benets and ability to meet growing populations' food demands and the environmental and human health risks associated with using reclaimed wastewater as an irrigation source. More research is needed to fully understand these risks to ensure agricultural sustainability to guide future water reuse policies.
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